Formanden har ordet: Vækstplan for life science vil gøre en forskel 20 March 2018
For et par uger siden præsenterede regeringen sin længe ventede Vækstplan for life science. I DANSK... Read more
For et par uger siden præsenterede regeringen sin længe ventede Vækstplan for life science. I DANSK... Read more
Appoints Internationally Renowned Scientific Advisors COPENHAGEN, Denmark— 8 February 2018: Acesion... Read more
COPENHAGEN, Denmark (November 30, 2017) – Symphogen, a private clinical late-stage antibody oncology-focused... Read more
Common stock placement extended to a total of $80 million as Sofinnova Ventures and Scopia Capital Management... Read more
For knap to uger siden lykkedes det Orphazyme at gå på Børsen i København! Selskabet solgte 7,5 mio.... Read more
Orphazyme, a Danish biotech company with a late stage orphan drug pipeline, today published an offering... Read more
Det danske biotekselskab MonTa Biosciences har netop tegnet en licensaftale med UC San Diego Universitet... Read more
Orphazyme, a Danish biotech company with a late stage orphan drug pipeline, announces its intention to... Read more
Y-mAbs Therapeutics, Inc. closes $50 million in a private placement led by HBM Healthcare Investments... Read more